← Leaderboards
Margaret Juliana McElrath
Fred Hutchinson Cancer Center
$601,692,649
Attributed
$606,327,632
Total exposure
24
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $75.7M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$616,981,273 · 26
By mechanism
UM1$478,293,697 · 5
U01$97,770,029 · 3
U19$20,297,323 · 13
R01$9,305,716 · 2
C06$7,947,160 · 1
R37$3,362,348 · 1
Top collaborators
- Kenneth D Stuart15 shared
- Troy R Torgerson9 shared
- Rafi Ahmed6 shared
- William Nicholas Haining6 shared
- Ruobing Wang4 shared
- Aarthi Talla1 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Peter B. Gilbert$223,972,501
- Yunda Huang$75,372,842
- Holly Janes$70,932,400
- Lawrence Corey$859,232,520
- Dan H. Barouch$218,203,090
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
Research focus
VaccinesClinical TrialsImmune ResponseImmuneHiv VaccineLeadershipHiv InfectionsHiv Vaccine Trials NetworkResponseImmunityVaccinationVaccine DevelopmentHiv-1BaseClinical ResearchImmunologyRegimenInvestigationVaccine EfficacyAdultEfficacy TrialInsightOperationInfection
Grant awards (138)
HIV Vaccine Trials Network Laboratory Center$30,362,486
UM1 · FY2025 · AI · contact PI
Upgrading Institutional Capacity with a BSL-3 Facility for Multidisciplinary Biomedical Research$7,947,160
C06 · FY2025 · OD · contact PI
HIV Vaccine Trials Network Laboratory Center$6,451,056
UM1 · FY2025 · AI · contact PI
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization$2,100,000
U19 · FY2025 · AI
Seattle Clinical Trials Unit$1,679,850
UM1 · FY2025 · AI · contact PI
Seattle Clinical Trials Unit$1,077,209
UM1 · FY2025 · AI · contact PI
Core-002$971,739
U19 · FY2025 · AI
Project-004$364,996
U19 · FY2025 · AI
Core-001$309,424
U19 · FY2025 · AI
Project-002$160,656
U19 · FY2025 · AI
Admin-Core-001$153,526
U19 · FY2025 · AI
Project-003$139,659
U19 · FY2025 · AI
HIV Vaccine Trials Network Laboratory Center$28,707,507
UM1 · FY2024 · AI · contact PI
HIV Vaccine Trials Network Laboratory Center - B-Cell and Molecular Assay Multi-year Supplement$3,287,548
UM1 · FY2024 · AI · contact PI
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization$2,100,000
U19 · FY2024 · AI
Seattle-Lausanne Clinical Trials Unit$1,857,698
UM1 · FY2024 · AI · contact PI
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core$198,000
U19 · FY2024 · AI · contact PI
Scientific Project 2: HIV AIDS Defining molecular signatures in humans following vaccination that can inform pathways to protective immunity against HIV-1 infection$144,133
U19 · FY2024 · AI · contact PI
HIV Vaccine Trials Network Laboratory Center$38,409,483
UM1 · FY2023 · AI · contact PI
CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern - LC GY18$3,200,000
UM1 · FY2023 · AI · contact PI
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization$2,100,000
U19 · FY2023 · AI
Seattle-Lausanne Clinical Trials Unit$1,857,247
UM1 · FY2023 · AI · contact PI
CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern - LC Repository$1,748,110
UM1 · FY2023 · AI · contact PI
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core$185,244
U19 · FY2023 · AI · contact PI
Scientific Project 2: HIV AIDS Defining molecular signatures in humans following vaccination that can inform pathways to protective immunity against HIV-1 infection$134,844
U19 · FY2023 · AI · contact PI
HIV Vaccine Trials Network Laboratory Center$30,868,345
UM1 · FY2022 · AI · contact PI
HIV Vaccine Trials Network Laboratory Center$11,222,643
UM1 · FY2022 · AI · contact PI
CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection LC 3$8,696,751
UM1 · FY2022 · AI · contact PI
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine - LC3$4,637,125
UM1 · FY2022 · AI · contact PI
HIV Vaccine Trials Network Laboratory Center$4,367,621
UM1 · FY2022 · AI · contact PI
HIV Vaccine Trials Network Laboratory Center$3,805,979
UM1 · FY2022 · AI · contact PI
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3$3,544,100
UM1 · FY2022 · AI · contact PI
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization$2,071,529
U19 · FY2022 · AI
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3$1,324,786
UM1 · FY2022 · AI · contact PI
Seattle-Lausanne Clinical Trials Unit$1,226,577
UM1 · FY2022 · AI · contact PI
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine LC3$1,077,287
UM1 · FY2022 · AI · contact PI
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals$929,677
UM1 · FY2022 · AI · contact PI
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3$586,880
UM1 · FY2022 · AI · contact PI
CoVPN 3002 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222 for the Prevention of COVID-19 LC2$531,957
UM1 · FY2022 · AI · contact PI
Seattle-Lausanne Clinical Trials Unit$386,073
UM1 · FY2022 · AI · contact PI
Scientific Project 2: HIV AIDS Defining molecular signatures in humans following vaccination that can inform pathways to protective immunity against HIV-1 infection$204,536
U19 · FY2022 · AI · contact PI
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core$176,817
U19 · FY2022 · AI · contact PI
HIV Vaccine Trials Network Laboratory Center$33,072,609
UM1 · FY2021 · AI · contact PI
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Lab$14,980,054
UM1 · FY2021 · AI · contact PI
Seattle-Lausanne Clinical Trials Unit$1,608,983
UM1 · FY2021 · AI · contact PI
Immune responses to HIV virus immunization - Project 2$596,365
U19 · FY2021 · AI · contact PI
Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core$162,800
U19 · FY2021 · AI · contact PI
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC$29,952,323
UM1 · FY2020 · AI · contact PI
LC: HIV Vaccine Trials Network$23,169,744
UM1 · FY2020 · AI · contact PI
CoVPN 3002 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222 for the Prevention of COVID-19 LAB$6,554,653
UM1 · FY2020 · AI · contact PI
Seattle-Lausanne-Kampala CTU$1,916,595
UM1 · FY2020 · AI · contact PI
Immune responses to HIV virus immunization - Project 2$596,365
U19 · FY2020 · AI · contact PI
SARS-CoV-2 testing at the Seattle Vaccine and Prevention CRS (30331)$299,401
UM1 · FY2020 · AI · contact PI
Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core$162,798
U19 · FY2020 · AI · contact PI
LC: HIV Vaccine Trials Network$25,705,512
UM1 · FY2019 · AI · contact PI
Seattle-Lausanne-Kampala CTU$2,302,202
UM1 · FY2019 · AI · contact PI
Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core$1,409,149
U19 · FY2019 · AI · contact PI
Immune responses to HIV virus immunization - Project 2$700,977
U19 · FY2019 · AI · contact PI
LC: HIV Vaccine Trials Network$35,486,174
UM1 · FY2018 · AI · contact PI
Seattle-Lausanne-Kampala CTU$1,310,445
UM1 · FY2018 · AI · contact PI
Immune responses to HIV virus immunization - Project 2$475,999
U19 · FY2018 · AI · contact PI
Support Component D/Vaccine Discovery, Concept to Clinic$446,359
UM1 · FY2018 · AI · contact PI
Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core$145,358
U19 · FY2018 · AI · contact PI
Immune responses to HIV virus immunization - Project 2$140,001
U19 · FY2018 · AI · contact PI
Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core$39,964
U19 · FY2018 · AI · contact PI
LC: HIV Vaccine Trials Network$21,415,215
UM1 · FY2017 · AI · contact PI
Seattle-Lausanne-Kampala CTU$1,284,773
UM1 · FY2017 · AI · contact PI
Immune responses to HIV virus immunization - Project 2$636,026
U19 · FY2017 · AI · contact PI
Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core$196,086
U19 · FY2017 · AI · contact PI
Support Component D/Vaccine Discovery, Concept to Clinic$22,847
UM1 · FY2017 · AI · contact PI
LC: HIV Vaccine Trials Network$14,697,164
UM1 · FY2016 · AI · contact PI
Seattle-Lausanne-Kampala CTU$1,310,443
UM1 · FY2016 · AI · contact PI
Support Component D/Vaccine Discovery, Concept to Clinic$99,801
UM1 · FY2016 · AI · contact PI
LC: HIV Vaccine Trials Network$16,885,478
UM1 · FY2015 · AI · contact PI
Seattle-Lausanne-Kampala CTU$1,476,996
UM1 · FY2015 · AI · contact PI
Functional genomic analysis of the CD8 T cell response to HIV vaccines in$767,357
R01 · FY2015 · AI
Immune Profile and Network Analysis of Malaria Infection and Vaccination$246,286
U19 · FY2015 · AI
Support Component D/Vaccine Discovery, Concept to Clinic$99,258
UM1 · FY2015 · AI · contact PI
LC: HIV Vaccine Trials Network$11,216,519
UM1 · FY2014 · AI · contact PI
Seattle-Lausanne-Kampala CTU$2,039,318
UM1 · FY2014 · AI · contact PI
Functional genomic analysis of the CD8 T cell response to HIV vaccines in$767,357
R01 · FY2014 · AI
Support Component D/Vaccine Discovery, Concept to Clinic$96,454
UM1 · FY2014 · AI · contact PI
HVTN Laboratory Program$7,256,662
UM1 · FY2013 · AI · contact PI
Functional genomic analysis of the CD8 T cell response to HIV vaccines in$721,315
R01 · FY2013 · AI
Seattle Vaccine Trials Unit$551,370
UM1 · FY2013 · AI · contact PI
Immune Profile and Network Analysis of Malaria Infection and Vaccination$481,984
U19 · FY2013 · AI
Immune Signatures Associated with Plasmodium falciparum Control Following Natural$387,228
U19 · FY2013 · AI · contact PI
Support Component D/Vaccine Discovery, Concept to Clinic$110,888
UM1 · FY2013 · AI · contact PI
HVTN Laboratory Program$13,310,092
UM1 · FY2012 · AI · contact PI
Functional genomic analysis of the CD8 T cell response to HIV vaccines in$767,357
R01 · FY2012 · AI
Seattle Vaccine Trials Unit$592,662
UM1 · FY2012 · AI · contact PI
Immune Profile and Network Analysis of Malaria Infection and Vaccination$512,750
U19 · FY2012 · AI
Immune Signatures Associated with Plasmodium falciparum Control Following Natural$277,709
U19 · FY2012 · AI · contact PI
Support Component D/Vaccine Discovery, Concept to Clinic$91,322
UM1 · FY2012 · AI · contact PI
HVTN Laboratory Program$17,087,386
UM1 · FY2011 · AI · contact PI
Functional genomic analysis of the CD8 T cell response to HIV vaccines in$1,065,338
R01 · FY2011 · AI
Immune Profile and Network Analysis of Malaria Infection and Vaccination$518,117
U19 · FY2011 · AI
Seattle Vaccine Trials Unit$469,361
U01 · FY2011 · AI · contact PI
Immune Signatures Associated with Plasmodium falciparum Control Following Natural$286,685
U19 · FY2011 · AI · contact PI
HVTN Laboratory Program$13,724,431
U01 · FY2010 · AI · contact PI
Functional genomic analysis of the CD8 T cell response to HIV vaccines in$763,750
R01 · FY2010 · AI
Immune Profile and Network Analysis of Malaria Infection and Vaccination$522,975
U19 · FY2010 · AI
Seattle Vaccine Trials Unit$522,242
U01 · FY2010 · AI · contact PI
Immune Signatures Associated with Plasmodium falciparum Control Following Natural$286,598
U19 · FY2010 · AI · contact PI
HIV-1 Cellular Immunity in Exposed Seronegatives$184,863
R01 · FY2010 · AI · contact PI
HVTN Laboratory Program$20,409,370
U01 · FY2009 · AI · contact PI
Seattle Vaccine Trials Unit$511,498
U01 · FY2009 · AI · contact PI
HIV-1 Cellular Immunity in Exposed Seronegatives$423,715
R01 · FY2009 · AI · contact PI
HVTN Laboratory Program$15,927,918
U01 · FY2008 · AI · contact PI
Seattle Vaccine Trials Unit$561,625
U01 · FY2008 · AI · contact PI
HIV-1 Cellular Immunity in Exposed Seronegatives$413,373
R01 · FY2008 · AI · contact PI
HVTN Laboratory Program$15,461,760
U01 · FY2007 · AI · contact PI
Seattle Vaccine Trials Unit$939,387
U01 · FY2007 · AI · contact PI
HIV-1 Cellular Immunity in Exposed Seronegatives$567,555
R01 · FY2007 · AI · contact PI
Mucosal CTL Induction After HIV Exposure & Vaccination$463,199
R37 · FY2007 · AI · contact PI
HVTN Laboratory Program$17,093,162
U01 · FY2006 · AI · contact PI
HIV-1 Cellular Immunity in Exposed Seronegatives$584,643
R01 · FY2006 · AI · contact PI
HIV VACCINES TRIAL UNITS$501,264
U01 · FY2006 · AI · contact PI
Mucosal CTL Induction After HIV Exposure & Vaccination$463,195
R37 · FY2006 · AI · contact PI
HIV VACCINES TRIAL UNITS$2,155,503
U01 · FY2005 · AI
HIV-1 Cellular Immunity in Exposed Seronegatives$505,444
R01 · FY2005 · AI
Mucosal CTL Induction After HIV Exposure &Vaccination$460,585
R37 · FY2005 · AI
HIV VACCINES TRIAL UNITS$1,912,186
U01 · FY2004 · AI
Mucosal CTL Induction After HIV Exposure &Vaccination$447,226
R37 · FY2004 · AI
HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES$369,400
R01 · FY2004 · AI
HIV VACCINES TRIAL UNITS$1,865,844
U01 · FY2003 · AI
Mucosal CTL Induction After HIV Exposure &Vaccination$450,258
R37 · FY2003 · AI
HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES$358,894
R01 · FY2003 · AI
HIV VACCINES TRIAL UNITS$1,964,254
U01 · FY2002 · AI
MUCOSAL CTL INDUCTION AFTER HIV EXPOSURE AND VACCINATION$369,966
R37 · FY2002 · AI
HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES$348,594
R01 · FY2002 · AI
Conference on HIV-1 Protection &Control by Vaccination$5,000
R13 · FY2002 · AI
HIV VACCINES TRIAL UNITS$1,916,713
U01 · FY2001 · AI
MUCOSAL CTL INDUCTION AFTER HIV EXPOSURE AND VACCINATION$359,190
R37 · FY2001 · AI
HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES$338,592
R01 · FY2001 · AI
HIV VACCINES TRIAL UNITS$1,833,511
U01 · FY2000 · AI
HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES$358,169
R01 · FY2000 · AI
MUCOSAL CTL INDUCTION AFTER HIV EXPOSURE AND VACCINATION$348,729
R37 · FY2000 · AI